Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with 90 Y Glass Microspheres
Journal of Nuclear Medicine · 2023-07 · 64 (7) · 1102-1108
DOI: 10.2967/jnumed.122.264996 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 08.06.2023. Verfasst von Masao Watanabe und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Clinic Essen, Essen, Germany. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Embolization, Therapeutic, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Personalized dosimetry holds promise to improve radioembolization treatment outcomes in hepatocellular carcinoma (HCC) patients. To this end, tolerance absorbed doses for nontumor liver tissue are assessed by calculating the mean absorbed dose to the whole nontumor liver tissue (AD-WNTLT), which may be limited by its neglect of nonuniform dose distribution. Thus, we analyzed whether voxel-based dosimetry could be more accurate in predicting hepatotoxicity in HCC patients undergoing radioembolization.
Methods
In total, 176 HCC patients were available for this retrospective analysis; of these, 78 underwent partial- and 98 whole-liver treatment. Posttherapeutic changes in bilirubin were graded using the Common Terminology Criteria for Adverse Events. We performed voxel-based and multicompartment dosimetry using pretherapeutic 99mTc-labeled human serum albumin SPECT and contrast-enhanced CT/MRI and defined the following dosimetry parameters: AD-WNTLT; the nontumor liver tissue volume exposed to at least 20 Gy (V20), at least 30 Gy (V30), and at least 40 Gy (V40); and the threshold absorbed dose to the 20% (AD-20) and 30% (AD-30) of nontumor liver tissue with the lowest absorbed dose. Their impact on hepatotoxicity after 6 mo was analyzed using the area under the receiver-operating-characteristic curve; thresholds were identified using the Youden index.
Results
The area under the curve for prediction of posttherapeutic grade 3+ increases in bilirubin was acceptable for V20 (0.77), V30 (0.78), and V40 (0.79), whereas it was low for AD-WNTLT (0.67). The predictive value could further be increased in the subanalysis of patients with whole-liver treatment, where a good discriminatory power was found for V20 (0.80), V30 (0.82), V40 (0.84), AD-20 (0.80), and AD-30 (0.82) and an acceptable discriminatory power was found for AD-WNTLT (0.63). The accuracies of V20 (P = 0.03), V30 (P = 0.009), V40 (P = 0.004), AD-20 (P = 0.04), and AD-30 (P = 0.02) were superior to that of AD-WNTLT but did not differ significantly from each other. The respective thresholds were 78% (V30), 72% (V40), and 43 Gy (AD-30). Statistical significance was not reached for partial-liver treatment.
Conclusion
Voxel-based dosimetry may more accurately predict hepatotoxicity than multicompartment dosimetry in HCC patients undergoing radioembolization, which could enable dose escalation or deescalation with the intent to optimize treatment response. Our results indicate that a V40 of 72% may be particularly useful in whole-liver treatment. However, further research is warranted to validate these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Clinic Essen, Essen, Germany.
- University of Duisburg-Essen and German Cancer Consortium-University Hospital, Essen, Germany.
- Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Clinic Essen, Essen, Germany.
- Department of Gastroenterology and Hepatology, University Clinic Essen, Essen, Germany; and.
- Institute for AI in Medicine, University Medicine Essen, Essen, Germany.
- Department of Nuclear Medicine, University Clinic Essen, Essen, Germany; manuel.weber@uk-essen.de.
Zitieren
APA
Watanabe, M., Grafe, H., Theysohn, J., Schaarschmidt, B., Ludwig, J., Jochheim, L., Jeschke, M., Schmidt, H., Fendler, W. P., Moraitis, A., Herrmann, K., Pomykala, K. L., & Weber, M. (2023). Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with 90 Y Glass Microspheres. Journal of Nuclear Medicine, 64(7), 1102-1108. https://doi.org/10.2967/jnumed.122.264996
Vancouver
Watanabe M, Grafe H, Theysohn J, Schaarschmidt B, Ludwig J, Jochheim L, et al. Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with 90 Y Glass Microspheres. Journal of Nuclear Medicine. 2023;64(7):1102-1108. doi:10.2967/jnumed.122.264996
BibTeX
@article{Watanabe2023,
author = {Watanabe, Masao and Grafe, Hong and Theysohn, Jens and Schaarschmidt, Benedikt and Ludwig, Johannes and Jochheim, Leonie and Jeschke, Matthias and Schmidt, Hartmut and Fendler, Wolfgang P and Moraitis, Alexandros and Herrmann, Ken and Pomykala, Kelsey L and Weber, Manuel},
title = {Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with 90 Y Glass Microspheres},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {7},
pages = {1102--1108},
doi = {10.2967/jnumed.122.264996}
}
EUVIMED